Wave Life Sciences Prices Upsized $200 Million Public Offering of Ordinary Shares and Pre-Funded Warrants
Rhea-AI Summary
Wave Life Sciences (Nasdaq: WVE) has announced the pricing of its upsized public offering of ordinary shares and pre-funded warrants, aiming to raise approximately $200 million in gross proceeds. The offering includes 23,125,001 ordinary shares at $8.00 per share and pre-funded warrants to purchase up to 1,875,023 ordinary shares at $7.9999 per warrant. The company has also granted underwriters a 30-day option to purchase up to an additional 3,750,000 ordinary shares. The offering is expected to close around September 27, 2024. J.P. Morgan and Leerink Partners are acting as joint book-running managers, with Truist Securities and Mizuho as book-runners. The offering is being made through a prospectus and related supplement, with details available on the SEC's website.
Positive
- Successful pricing of an upsized public offering, potentially raising $200 million in gross proceeds
- Additional 30-day option for underwriters to purchase up to 3,750,000 more ordinary shares
- Strong support from reputable financial institutions as book-running managers and book-runners
Negative
- Potential dilution of existing shareholders' ownership due to the issuance of new shares
- Increase in outstanding shares may put downward pressure on the stock price
News Market Reaction
On the day this news was published, WVE declined 10.99%, reflecting a significant negative market reaction.
Data tracked by StockTitan Argus on the day of publication.
CAMBRIDGE, Mass., Sept. 25, 2024 (GLOBE NEWSWIRE) -- Wave Life Sciences Ltd. (Nasdaq: WVE), a clinical-stage biotechnology company focused on unlocking the broad potential of RNA medicines to transform human health, announced today the pricing of its previously announced underwritten public offering of 23,125,001 of its ordinary shares at a price to the public of
Gross proceeds to Wave Life Sciences from the offering are expected to be approximately
J.P. Morgan and Leerink Partners are acting as joint book-running managers for the offering. Truist Securities and Mizuho are acting as book-runners for the offering.
The offering is being made only by means of a prospectus and related prospectus supplement forming part of a shelf registration statement that was previously filed with and declared effective by the Securities and Exchange Commission (“SEC”). The preliminary prospectus supplement and accompanying base prospectus relating to the offering were filed with the SEC on September 24, 2024. The final prospectus supplement and the accompanying prospectus will be filed with the SEC and will be available on the SEC’s website located at http://www.sec.gov, copies of which may be obtained, when available, from J.P. Morgan Securities LLC, c/o Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, NY 11717, or by email at prospectus-eq_fi@jpmchase.com and postsalemanualrequests@broadridge.com; or from Leerink Partners LLC, Syndicate Department, 53 State Street, 40th Floor, Boston, MA 02109, or by telephone at (800) 808-7525, ext. 6105, or by email at syndicate@leerink.com.
This press release shall not constitute an offer to sell, or a solicitation of an offer to buy, nor will there be any sale of these securities in any state or other jurisdiction in which such an offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or other jurisdiction.
About Wave Life Sciences
Wave Life Sciences (Nasdaq: WVE) is a biotechnology company focused on unlocking the broad potential of RNA medicines to transform human health. Wave’s RNA medicines platform, PRISM®, combines multiple modalities, chemistry innovation and deep insights in human genetics to deliver scientific breakthroughs that treat both rare and prevalent disorders. Its toolkit of RNA-targeting modalities includes editing, splicing, RNA interference and antisense silencing, providing Wave with unmatched capabilities for designing and sustainably delivering candidates that optimally address disease biology. Wave’s diversified pipeline includes clinical programs in Duchenne muscular dystrophy, Alpha-1 antitrypsin deficiency and Huntington’s disease, as well as a preclinical program in obesity. Driven by the calling to “Reimagine Possible”, Wave is leading the charge toward a world in which human potential is no longer hindered by the burden of disease. Wave is headquartered in Cambridge, MA.
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended. The words “may,” “will,” “could,” “would,” “should,” “expect,” “plan,” “anticipate,” “intend,” “believe,” “estimate,” “predict,” “project,” “potential,” “continue,” “target” and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Forward-looking statements include statements regarding the closing of the public offering of ordinary shares and pre-funded warrants to purchase ordinary shares. These statements are subject to various risks and uncertainties, actual results could differ materially from those projected and Wave cautions investors not to place undue reliance on the forward-looking statements in this press release. These risks and uncertainties include, without limitation, risks and uncertainties related to satisfaction of customary closing conditions related to the public offering. There can be no assurance that Wave will be able to complete the public offering on the anticipated terms, or at all. Any forward-looking statements in this press release are based on management’s current expectations and beliefs and are subject to a number of risks, uncertainties and important factors that may cause actual events or results to differ materially from those expressed or implied by any forward-looking statements contained in this press release, including, without limitation, the risks and uncertainties described in the section entitled “Risk Factors” in Wave’s preliminary prospectus supplement related to the proposed offering filed with the SEC on September 24, 2024 and Wave’s most recent Annual Report on Form 10-K filed with the SEC, as amended, and in other filings Wave makes with the SEC from time to time. Wave undertakes no obligation to update the information contained in this press release to reflect subsequently occurring events or circumstances.
Investor Contact:
Kate Rausch
+1 617-949-4827
krausch@wavelifesci.com
Media Contact:
Alicia Suter
+1 617-949-4817
asuter@wavelifesci.com
FAQ
What is the size of Wave Life Sciences' (WVE) public offering?
How many ordinary shares is Wave Life Sciences (WVE) offering in its public offering?
What is the price per ordinary share in Wave Life Sciences' (WVE) public offering?
When is the expected closing date for Wave Life Sciences' (WVE) public offering?
Who are the joint book-running managers for Wave Life Sciences' (WVE) public offering?
